Boosted by the recent US Food and Drug Administration approval for its Simlandi (adalimumab-ryvk) biosimilar –the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira – Alvotech will this month look to grab hold of in quick succession a further US biosimilar approval for autoimmune diseases.
The Icelandic firm anticipates FDA approval for its Stelara (ustekinumab) biosimilar product on 16 April 2024 ahead of an expected...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?